Advertisement
LABFF vs NVO
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LABFF is a Hold and NVO is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LABFF’s FA Score shows that 2 FA rating(s) are green whileNVO’s FA Score has 2 green FA rating(s).
- LABFF’s FA Score: 2 green, 3 red.
- NVO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NVO’s TA Score shows that 5 TA indicator(s) are bullish.
- NVO’s TA Score: 5 bullish, 4 bearish.
Price Growth
LABFF (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while NVO (@Pharmaceuticals: Major) price change was +2.60% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +4.25%. For the same industry, the average monthly price growth was +10.98%, and the average quarterly price growth was +78.05%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +2.79%. For the same industry, the average monthly price growth was +6.10%, and the average quarterly price growth was +13.36%.
Reported Earning Dates
NVO is expected to report earnings on Nov 05, 2025.
Industries' Descriptions
@Pharmaceuticals: Generic (+4.25% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
@Pharmaceuticals: Major (+2.79% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| LABFF | NVO | LABFF / NVO | |
| Capitalization | 3.38B | 226B | 1% |
| EBITDA | 203M | 147B | 0% |
| Gain YTD | 0.000 | -38.090 | - |
| P/E Ratio | 28.85 | 13.38 | 216% |
| Revenue | 749M | 303B | 0% |
| Total Cash | 47.6M | 41.6B | 0% |
| Total Debt | 129M | 119B | 0% |
NVO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 59 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 15 Undervalued | |
PROFIT vs RISK RATING 1..100 | 81 | |
SMR RATING 1..100 | 14 | |
PRICE GROWTH RATING 1..100 | 92 | |
P/E GROWTH RATING 1..100 | 98 | |
SEASONALITY SCORE 1..100 | 4 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| LABFF | NVO | |
|---|---|---|
| RSI ODDS (%) | N/A | 1 day ago 81% |
| Stochastic ODDS (%) | N/A | 1 day ago 61% |
| Momentum ODDS (%) | N/A | 1 day ago 73% |
| MACD ODDS (%) | N/A | 1 day ago 57% |
| TrendWeek ODDS (%) | 1 day ago 14% | 1 day ago 67% |
| TrendMonth ODDS (%) | 1 day ago 14% | 1 day ago 62% |
| Advances ODDS (%) | N/A | 1 day ago 67% |
| Declines ODDS (%) | N/A | 5 days ago 58% |
| BollingerBands ODDS (%) | N/A | 1 day ago 69% |
| Aroon ODDS (%) | N/A | 1 day ago 58% |
Advertisement
LABFF and
Correlation & Price change
A.I.dvisor indicates that over the last year, LABFF has been closely correlated with IMRN. These tickers have moved in lockstep 81% of the time. This A.I.-generated data suggests there is a high statistical probability that if LABFF jumps, then IMRN could also see price increases.
| Ticker / NAME | Correlation To LABFF | 1D Price Change % | ||
|---|---|---|---|---|
| LABFF | 100% | N/A | ||
| IMRN - LABFF | 81% Closely correlated | -0.55% | ||
| MNMD - LABFF | 47% Loosely correlated | -1.13% | ||
| CELZ - LABFF | 35% Loosely correlated | +1.63% | ||
| NVO - LABFF | 29% Poorly correlated | +2.87% | ||
| QSI - LABFF | 26% Poorly correlated | -1.79% | ||
More | ||||
NVO and
Correlation & Price change
A.I.dvisor indicates that over the last year, NVO has been closely correlated with NONOF. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if NVO jumps, then NONOF could also see price increases.
| Ticker / NAME | Correlation To NVO | 1D Price Change % | ||
|---|---|---|---|---|
| NVO | 100% | +2.87% | ||
| NONOF - NVO | 70% Closely correlated | +1.87% | ||
| TECH - NVO | 36% Loosely correlated | -0.26% | ||
| GMAB - NVO | 35% Loosely correlated | +1.44% | ||
| BCAB - NVO | 33% Loosely correlated | +0.99% | ||
| NVS - NVO | 32% Poorly correlated | +1.74% | ||
More | ||||